Introduction
Grepafloxacin is a synthetic fluoroquinolone with potent, broad-spectrum antibacterial activity; compared with other quinolones, it exhibits enhanced efficacy against Grampositive species. 1, 2 Its chemical structure is shown in Figure 1 . This review will consider the pharmacokinetics of grepafloxacin as determined following single and repeated doses in healthy volunteers. In addition, factors potentially affecting grepafloxacin absorption, pharmacokinetic parameters in different populations, interaction with other drugs, and penetration in different tissues, will be reviewed.
Pharmacokinetic characteristics

Pharmacokinetics following a single oral dose
A study in 18 healthy male subjects investigated the pharmacokinetic properties of grepafloxacin following a single oral dose. 3 Subjects received placebo and three of four possible grepafloxacin doses (200 mg, 400 mg, 600 mg or 800 mg). In addition, three subjects subsequently received a single dose of 1200 mg or placebo. Mean plasma profiles following single, oral dosing are shown in Figure 2 . Peak plasma levels were reached, on average, 2 h after the dose, then declined bi-exponentially. Plasma levels increased disproportionately with increasing dose. Grepafloxacin could be detected ( 5 ng/mL) in the plasma up to at least 72 h after administration of the recommended therapeutic doses. Table I shows the pharmacokinetic parameters of grepafloxacin determined in this study. The area under the plasma concentration-time curve between zero and infinity (AUC 0-) and the maximum observed plasma concentration (C max ) were found to increase more than proportionally with dose ( Figure 3 ), which was associated with a clear trend of a decrease in the apparent total clearance with increasing dose. While the apparent volume of distribution decreased from about 8 L/kg at the lower doses to about 6 L/kg at the higher doses, half-life values were similar
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Grepafloxacin is a fluoroquinolone antibiotic which is rapidly absorbed in healthy volunteers following oral dosing. It reaches peak plasma levels around 2 h after administration, then declines bi-exponentially, with an extended half-life of around 12 h. Grepafloxacin is eliminated primarily through metabolism and is excreted mainly in the faeces. Renal clearance accounts for only 10-15% of the administered dose. Grepafloxacin plasma concentrations increase disproportionately with increasing doses, but this is unlikely to be of clinical significance over the range of therapeutic doses. The rate and extent of absorption are not affected by food or elevated intragastric pH. The pharmacokinetics of grepafloxacin are affected by gender, with these differences relating to variations in body weight. No effect of age on the pharmacokinetics of grepafloxacin was found. Renal impairment does not affect grepafloxacin pharmacokinetics, whereas peak plasma concentrations, areas under plasma concentration-time curves and renal excretion are increased in patients with hepatic impairment. Grepafloxacin can be co-administered with warfarin and theophylline, though reduction of the theophylline dose is necessary. Following oral administration, higher grepafloxacin concentrations are achieved in lung and genital tissues than in serum, indicating its potential in the treatment of respiratory and sexually transmitted diseases. In addition, it exceeds therapeutically effective levels in bile and gall-bladder tissues, and accumulates in polymorphonuclear leucocytes such that it may be useful against intracellular pathogens.
across the dose range (around 12 h). Given the estimated absolute, oral bioavailability of grepafloxacin of around 72% (GlaxoWellcome, data on file), the high values obtained for apparent volume of distribution suggest extensive distribution of the antibiotic in the body.
Urinary excretion of unchanged grepafloxacin ranged from around 6% to around 14%, suggesting that metabolism rather than urinary excretion is the major elimination route. Saturation in the metabolism of grepafloxacin and possibly in the distribution into a peripheral compartment, as suggested by a decrease in the apparent total plasma clearance and in the apparent volume of distribution, could be the origin of the non-linear kinetics. However, this deviation from linearity is unlikely to be of clinical significance, since it was very small over the recommended range of therapeutic doses (400-600 mg od).
Pharmacokinetics following repeated oral dosing
The pharmacokinetics of grepafloxacin has also been studied following repeated oral dosing in 24 healthy volunteers. 3 Subjects received placebo or grepafloxacin, 400 mg or 800 mg od, for 14 days. Figure 4 shows the mean plasma profiles on days 7 and 14. As seen in the single-dose study, plasma profiles exhibited a bi-exponential decline, and plasma levels increased disproportionately with increasing dose. Trough plasma concentrations increased significantly during the first 3 days of dosing, reaching approximately 80% of steady-state levels. Steady state was reached on day 5 (400 mg dose) and day 7 (800 mg dose) of dosing. The similarity of plasma concentrations recorded on days 7 and 14 for each dose indicated that a steady state was maintained.
The pharmacokinetic parameters of grepafloxacin determined in this study are summarized in Table II . Values of C max , pre-dose plasma concentration (C trough ) and AUC within the dosing interval (AUC 0-24 h ), in addition to the percentage of dose excreted unchanged, were similar on days 7 and 14 for each dose. C max and C trough increased proportionally with the dose. However, the increase in AUC 0-24 h was more than proportional to the dose. Halflives were not determined on day 7 because of the short blood sampling period (i.e. 24 h) relative to the half-life of grepafloxacin. Similar half-lives (around 15 h) were determined for both doses after administration of the final dose ; , 1200 mg (n 2)) in healthy male subjects. The mean plasma concentrations for the 1200 mg dose are shown without S.D. as only two subjects were randomized to receive this dose. Adapted from Efthymiopoulos et al. 3 with permission.
on day 14. The renal clearance calculated on days 7 and 14 was similar for both grepafloxacin doses (about 0.05 L/h/kg).
Metabolism
The metabolism of grepafloxacin has been investigated in healthy volunteers. 4 Five metabolites have been identified, all of which have minimal antibacterial activity. Major metabolites identified included the 4 -glucuronide and 4 -sulphate conjugates of grepafloxacin, and oxidated metabolites, the most important of which was the (2-aminopropyl)amino metabolite, formed from the opening of the piperazinyl ring. The metabolites accounted for 10% of the dose in plasma, urine and faeces. The primary route of excretion of grepafloxacin has been shown to be in faeces, either via the bile or transmucosally.
5
Effect of food and gastric pH
Food has been shown to have little effect on fluoroquinolone absorption, 6 but it may reduce the rate of absorption and peak plasma concentration of some agents and so affect antibiotic efficacy. 7 A study of pharmacokinetics following administration of grepafloxacin 600 mg to 16 fasting and non-fasting healthy subjects found no significant effect of food, with the ratios of (log-transformed) C max , AUC 0-and AUC between zero and last quantifiable concentration (AUC t ) in fasting and nonfasting conditions being 0.96, 0.97 and 0.97, respectively (all 90% confidence intervals (CIs) fell between 0.91 and 1.01). 8 The elimination half-life was similarly unaffected by food.
37
Antacids containing aluminium and magnesium are thought to reduce the bioavailability of some fluoroquinolones through the formation of an insoluble metal-fluoroquinolone complex, rather than by elevation of intragastric pH. Fluoroquinolones are generally unaffected by concomitant administration of histamine H 2 -receptor antagonists, except when these agents interact with fluoroquinolones through inhibition of oxidative drug metabolism. 9 The pharmacokinetics of oral grepafloxacin 400 mg, administered alone or in combination with the H 2 -receptor antagonist famotidine 20 mg iv, has been studied in 16 healthy volunteers. 8 No significant differences in pharmacokinetic parameters were seen between subjects receiving grepafloxacin alone or concomitantly with famotidine. The ratio for AUC t was 1.02 (90% CI 0.97-1.09), for AUC 0-was 1.03 (90% CI 0.97-1.09), and for C max was 1.06 (90 % CI 0.97-1.16). ) on days 7 (solid lines) and 14 (dashed lines) following repeated oral administration of grepafloxacin, 400 mg ( ) or 800 mg ( ) od, to healthy male subjects. Pharmacokinetic data were not available for two subjects (one receiving each dose) on days 7 and 14, and for another three subjects on day 14 (two receiving 400 mg and one receiving 800 mg). Adapted with permission from Efthymiopoulos et al. Abbreviations as in Table I ; also: C trough , observed pre-dose plasma concentration; AUC 0-24 h , area under the plasma concentration-time curve within the dosing interval; ND, not determinable.
Age and gender
Gender and age can affect drug pharmacokinetics and so possibly affect antibiotic efficacy. 10, 11 Following administration of grepafloxacin 600 mg for 7 days to healthy volunteers aged 40 years or over, mean plasma concentrations were higher in females at all sample time points on days 1 and 7, irrespective of age.
12 Concentration-time profiles were similar in subjects of all ages. There were significant differences between male and female subjects on days 1 and 7 in all weight-dependent parameters (i.e. C max , AUC 0-24 h , apparent total clearance (Cl) normalized to the fraction (F) of the drug absorbed (Cl/F), apparent volume of distribution (V d ) normalized to F (V d /F), and average plasma concentration at steady state (C ss ), with the exception of renal clearance (Cl r ). C max , AUC 0-24h and C ss were notably higher, and Cl/F and V d /F were lower in females than in males. No significant differences between the sexes were noted for other pharmacokinetic parameters, and there was no significant interaction between age and gender. The geometric mean ratios of males to females (with 90% CI) for C max on days 1 and 7 were 0.72 (0.65, 0.79) and 0.74 (0.67, 0.82), respectively. The corresponding values for AUC 0-24 h were 0.75 (0.63, 0.83) and 0.75 (0.66, 0.85), respectively. After taking body weight (and in particular lean body mass) into account, however, no significant differences were found. Thus, differences in grepafloxacin pharmacokinetics between the sexes are primarily attributable to differences in body weight, and in particular to lean body mass.
Apart from Cl r /kg, and renal excretion on day 7, pharmacokinetic parameters measured on days 1 or 7 did not change significantly with increasing age. A decrease in renal function (measured by creatinine clearance) was seen with age, but there was no correlation between renal clear- 
Hepatic impairment
The effect of hepatic impairment on the pharmacokinetics of grepafloxacin has been studied in a trial of 14 healthy volunteers and 24 patients with varying degrees of hepatic disease. 13 Normal subjects and patients with mild (Child-Pugh class A) 14 and moderate (Child-Pugh class B) 14 hepatic impairment received grepafloxacin 400 mg od for 7 days. The pharmacokinetic parameters recorded for grepafloxacin in these subjects are shown in Table III .
Patients with mild or moderate hepatic impairment had significantly different values for C max , AUC 0-, Cl/F and the proportion of unchanged drug excreted in the urine compared with healthy subjects. The elimination half-life determined in patients with moderate hepatic impairment was higher than in healthy controls, while values for the apparent volume of distribution were lower in patients with mild hepatic impairment than in healthy controls.
Geometric mean ratios for pharmacokinetic parameters in healthy compared with hepatically impaired subjects indicated that peak grepafloxacin concentrations were increased by 36% and 48% in patients with mild or moderate hepatic impairment, respectively, and that apparent total clearance decreased by 33% and 55%, respectively.
Renal impairment
A study of 20 adults, including healthy subjects and patients with mild, moderate or severe renal impairment, Abbreviations as in Table I . investigated the effect of renal function on grepafloxacin pharmacokinetics. 15 Subjects received oral grepafloxacin 400 mg for 7 days. Table IV shows the pharmacokinetics of grepafloxacin in these subjects. On days 1 and 7 the only significant differences seen between healthy subjects (group 1) and subjects with renal impairment (group 2: mild; group 3: moderate; group 4: severe) were reductions in renal clearance (Cl r /kg; P 0.05; group 1 compared with groups 3 and 4) and in the proportion of grepafloxacin excreted unchanged in the urine (P 0.05; group 1 compared with group 4). Renal clearance (normalized for body weight) was also significantly different between subjects with mild and severe impairment on day 7. Higher peak concentrations and AUC values were seen in subjects with renal impairment compared with healthy subjects, but no significant differences in these parameters were noted between groups 2, 3 and 4. The lack of any significant difference between these groups in the ratios of C max and AUC 0-24 h on days 1 and 7 indicates that there was no increased accumulation of grepafloxacin in renally impaired subjects. A two-fold accumulation was observed after repeated administration of grepafloxacin, which was consistent with an effective half-life value of about 24 h. The discrepancy between the two half-life estimates (elimination and effective) in this study could be related to the differences in the calculation and significance of the two parameters, as well as the non-linearity in the kinetics of grepafloxacin. 
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Interaction with warfarin and theophylline
Two phase I studies have investigated the effect of coadministration of grepafloxacin with warfarin or theophylline. 16 In the first study, 16 subjects received warfarin 10 mg od for 2 days, followed by titrated doses of warfarin on days 3-10. The maintenance dose (the warfarin dose given on day 10) was designed to produce an international normalized ratio (INR) of 1.5-2.5, and was given on days 11-24. Grepafloxacin 600 mg od was given with warfarin on days 15-24, and was administered alone on days 25-28. Plasma grepafloxacin concentrations were similar in patients receiving grepafloxacin alone and grepafloxacin plus warfarin, suggesting that warfarin does not affect grepafloxacin pharmacokinetics. Data available from three of six subjects in group *Statistically significant difference (P 0.05) from healthy subjects (by Dunnett's test). **Statistically significant difference (P 0.05) from subjects in group 4 (by Tukey's test).
0.94 (95% CI 0.77-1.15). Thus grepafloxacin did not affect the pharmacodynamics of warfarin.
In the second study, 16 subjects received an iv test dose of theophylline (a 1 h infusion of aminophylline), followed 15 days later by an individualized dose of oral sustainedrelease theophylline tablets to produce an average steadystate concentration of 7.5 mg/L (range 5-10 mg/L). During the study, theophylline was administered every 12 h for 7 days, and on day 7 its pharmacokinetic profile was determined. Administration of placebo or grepafloxacin 600 mg od began on day 8. The pharmacokinetic profile obtained after co-administration of these agents was determined on day 17.
While mean serum theophylline concentrations were consistently higher in subjects receiving theophylline plus grepafloxacin compared with those receiving theophylline alone, theophylline appeared to have no effect on the pharmacokinetics of grepafloxacin. Grepafloxacin treatment was associated with significant increases in C max and AUC, and significant reductions in the apparent total clearance of theophylline. Values of theophylline apparent total clearance normalized to F, as measured during the dosing intervals 0-12 h and 12-24 h after the last dose of grepafloxacin (Cl/F 0-12 h and Cl/F 12-24 h ) decreased by 49% and 54%, respectively, during treatment with grepafloxacin, suggesting that halving theophylline maintenance doses is appropriate during grepafloxacin treatment. Mean trough plasma grepafloxacin concentrations on days 14-17 were not significantly different and were within 10% of each other, indicating that steady state had been achieved. 
Tissue penetration
Respiratory tissues
While serum concentrations and MICs are useful predictors of antibiotic efficacy against particular pathogens, antibiotic tissue concentrations in the lung may be more relevant to gauge the activity of agents used to treat respiratory tract infection. Following administration of grepafloxacin 400 mg od for 4 days to 24 adults undergoing diagnostic bronchoscopy for chest radiograph abnormalities or haemoptysis, antibiotic levels attained in the serum and several lung compartments were compared. 17 The mean serum antibiotic concentration was found to be 1.23 mg/L, a level surpassed in bronchial mucosa (3.13 mg/kg), epithelial lining fluid (12.21 mg/L) and alveolar macrophages (194.52 mg/L). The concentrations attained in all tissues exceeded MIC 90 s reported previously for many common respiratory pathogens. In addition, grepafloxacin concentrations in the bronchial mucosa significantly exceeded those achieved with ciprofloxacin and temafloxacin, 18, 19 and penetration of epithelial lining fluid and alveolar macrophages by grepafloxacin was much higher than that seen with temafloxacin. 20 
Bile and gall-bladder tissues
The penetration of bile and gall-bladder tissues by grepafloxacin and the extent of its biliary excretion have been studied. 21 Grepafloxacin 300 mg od was given to six patients undergoing cholecystectomy, with dosing starting 3 days before surgery. Grepafloxacin concentrations in serum, gall-bladder tissue and bile at 2-5 h were 1.8 mg/L (mean 0.9 mg/L), 9.6 mg/kg (mean 5.6 mg/kg) and 189 mg/L (mean 50.8 mg/L), respectively. The common bile duct con- Abbreviations as in Table I ; NA: not applicable; ND: not determined.
centration, determined in one patient, was 6.7 mg/L. Concentrations in gall-bladder tissue and bile were higher than those attained in blood, and most exceeded the MICs for common biliary pathogens.
Gynaecological tissues
Effective penetration into female genital tissues has been reported following oral therapy with grepafloxacin 200 mg and 300 mg for 3-14 days. 22 Following dosing in 31 patients, the serum grepafloxacin concentration in uterine arterial blood was similar to that in cubital venous blood, with C max being recorded as 0.61-0.62 mg/L (200 mg) and 1.23-1.25 mg/L (300 mg). T max was 4-5 h after oral administration. Genital tissue concentrations were again higher than serum concentrations, with C max values in the endometrium, myometrium, cervix, portio vaginalis, ovary and oviduct of 4.43 mg/kg, 2.36 mg/kg, 1.49 mg/kg, 1.50 mg/kg, 2.98 mg/kg and 1.13 mg/kg (200 mg dose), and 6.44 mg/kg, 4.21 mg/kg, 3.42 mg/kg, 2.60 mg/kg, 5.22 mg/kg and 3.63 mg/kg (300 mg dose), respectively. The ratio of each tissue concentration to the maximum serum concentrations was 2.1-5.2, indicating a high degree of penetration into these tissues.
Prostatic tissues
A study of serum and tissue concentrations has found that grepafloxacin concentrations were 0.7-9.3 times higher in the prostate and 2.6-7.9 times higher in the testis than in serum. 23 
Human polymorphonuclear leucocytes
Fluorimetric assay has been used to quantify the penetration of human polymorphonuclear leucocytes (PMNs) by quinolones. 24 Penetration of PMNs isolated from healthy volunteers, as determined by the intracellular/extracellular concentration ratio, was highest for grepafloxacin (66.2) compared with levofloxacin (9.8), ofloxacin (7.6) and DR-3354 (5.8). Elution of grepafloxacin and ofloxacin from cells was rapid, but elution of grepafloxacin decreased at high extracellular pH and increased at low extracellular pH.
Conclusions
Grepafloxacin is absorbed rapidly following oral dosing, reaching peak plasma concentrations around 2 h after administration. It is extensively distributed in the body and is eliminated primarily by metabolism.
The disproportionate increase in AUCs after administration of both single and repeated increasing doses indicates non-linear kinetics. This could be explained by saturation in grepafloxacin metabolism, and possibly by distribution into a peripheral compartment. However, deviation from linearity is unlikely to be of clinical significance as it was small over the range of therapeutic doses (400 mg and 600 mg). Elimination half-life and renal clearance did not change with increasing dose in either the single-dose or repeated-dose study.
The extent and rate of absorption of grepafloxacin in healthy subjects were not found to be affected by food or elevated intragastric pH. The pharmacokinetics of grepafloxacin did not change with increasing age. Gender had a significant effect on grepafloxacin pharmacokinetics, with plasma levels in females being higher than in males. This difference, however, is related to variations in body weight and was of no clinical relevance. Thus, dose adjustment is not necessary on the basis of age or gender.
The pharmacokinetics of grepafloxacin are not significantly affected by renal impairment and this is consistent with the low urinary excretion ( 10%) of grepafloxacin. Therefore, dose adjustment in patients with renal dysfunction appears unnecessary. In subjects with mild or moderate liver impairment, peak plasma concentrations, AUCs and renal excretion of grepafloxacin are significantly increased compared with healthy controls. These findings are not unexpected given that grepafloxacin is metabolized predominantly in the liver. In subjects with mild liver impairment, a 400 mg dose would be expected to yield plasma concentrations similar to those seen following a 600 mg dose in healthy subjects. Grepafloxacin administration is not recommended in patients with moderate or severe liver impairment.
Theophylline clearance is approximately halved during co-administration with grepafloxacin, and so the maintenance dose of theophylline should be halved if the two drugs are to be given simultaneously. Conversely, theophylline has no effect on grepafloxacin pharmacokinetics. No dose adjustments of warfarin or grepafloxacin are necessary if these agents are given concomitantly.
The marked concentration of grepafloxacin in bronchial mucosa, epithelial lining fluid and macrophages suggests a clinical role for this agent in respiratory tract infection caused by Gram-positive and Gram-negative bacteria, as well as intracellular pathogens such as Chlamydia spp., Mycoplasma spp. and Legionella spp. In addition, the high rate of penetration into female and male genital tissues by grepafloxacin suggests that it may be useful in conditions such as urethritis and cervicitis. Grepafloxacin also attains concentrations in bile and gall-bladder tissues that exceed therapeutically effective levels for many pathogens.
